26.39

1.20% -0.32

Tg Therapeutics Inc (TGTX)

Overview News Price History Option Chain Financials Why TGTX Down? Discussions Forecast Stock Split

Tg Therapeutics Inc stock is traded at $26.39, with a volume of 4.56M. It is down -1.20% in the last 24 hours and down -28.84% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Previous Close:

$26.71

Open:

$26.14

24h Volume:

4.56M

Relative Volume:

2.20

Market Cap:

$4.19B

Revenue:

$264.79M

Net Income/Loss:

$-14.36M

P/E Ratio:

-239.91

EPS:

-0.11

Net Cash Flow:

$-28.11M

1W Performance:

-8.11%

1M Performance:

-28.84%

6M Performance:

-15.17%

1Y Performance:

+32.48%

1-Day Range:

$25.28

$27.37

1-Week Range:

$25.28

$29.15

52-Week Range:

$20.05

$46.48

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name

Tg Therapeutics Inc

Sector

Healthcare (1164)

Industry

Biotechnology (649)

Phone

(212) 554-4484

Address

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY

Employee

352

Twitter

@TGTherapeutics

Next Earnings Date

2025-03-03

Latest SEC Filings

TGTX's Discussions on Twitter

Compare TGTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TGTX Tg Therapeutics Inc	26.39	4.24B	264.79M	-14.36M	-28.11M	-0.11
VRTX Vertex Pharmaceuticals Inc	374.46	93.98B	11.42B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	435.00	57.53B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	545.94	59.67B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	638.90	40.50B	3.05B	1.28B	-614.78M	19.58
ONC Beone Medicines Ltd Adr	289.75	34.26B	3.81B	-644.79M	-669.77M	-6.24

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-25	Resumed	Goldman	Neutral
Oct-29-24	Initiated	TD Cowen	Buy
Aug-02-23	Upgrade	Goldman	Sell → Neutral
Jun-26-23	Resumed	Jefferies	Buy
May-20-22	Initiated	BofA Securities	Underperform
Feb-23-22	Reiterated	B. Riley Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-19-21	Reiterated	H.C. Wainwright	Buy
Sep-01-20	Initiated	JP Morgan	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Jun-05-20	Initiated	Evercore ISI	Outperform
Jan-17-20	Reiterated	H.C. Wainwright	Buy
Nov-27-19	Resumed	B. Riley FBR	Buy
Feb-06-19	Resumed	Jefferies	Buy
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy
Nov-14-17	Resumed	H.C. Wainwright	Buy
Apr-25-17	Initiated	Jefferies	Buy
Mar-06-17	Reiterated	FBR & Co.	Outperform
Oct-06-16	Resumed	Brean Capital	Buy
May-27-16	Initiated	SunTrust	Buy
Dec-01-15	Initiated	FBR Capital	Outperform
Sep-09-15	Initiated	Raymond James	Strong Buy
Aug-12-15	Resumed	H.C. Wainwright	Buy
Jun-19-15	Reiterated	Brean Capital	Buy
Dec-11-14	Reiterated	ROTH Capital	Buy
Dec-10-14	Reiterated	ROTH Capital	Buy

View All

Tg Therapeutics Inc Stock (TGTX) Latest News

Aug 11, 2025

Navigating AI Risks: TG Therapeutics Faces Regulatory and Legal Challenges - The Globe and Mail

Aug 11, 2025

Aug 10, 2025

TG Therapeutics: Strategic Capital Flexibility Fuels Briumvi's Global Expansion and R&D Momentum - AInvest

Aug 08, 2025

TG THERAPEUTICS, INC. SEC 10-Q Report - TradingView

Aug 08, 2025

TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline - MSN

Aug 08, 2025

Aug 06, 2025

TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN

Aug 06, 2025

TG Therapeutics falls after Q2 miss despite guidance raise - MSN

Aug 06, 2025

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - MSN

Aug 06, 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025

TR | OpenAI4o Maintains TG Therapeutics(TGTX.US) With Hold Rating, Cuts Target Price to $30 - 富途牛牛

Aug 06, 2025

TGTX Stock Falls 14.1% Amid Market Volatility - AInvest

Aug 06, 2025

TGTX Raises FY25 Revenue Projection, BRIUMVI Target Increased - AInvest

Aug 06, 2025

Aug 05, 2025

TG Therapeutics’ Earnings Call Highlights BRIUMVI Success - TipRanks

Aug 05, 2025

Tg Therapeutics shares fall 1.06% after-hours as clinical trial updates and legal risks weigh on sentiment. - AInvest

Aug 05, 2025

TGTX Down As Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - Barchart.com

Aug 05, 2025

New Lantern Expands AI Radiology Platform with Mammography and PET/CT Viewers - AInvest

Aug 05, 2025

TG Therapeutics (TGTX) Misses Q2 Earnings Estimates - MSN

Aug 05, 2025

TG Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st

Aug 05, 2025

TG Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat

Aug 05, 2025